BRIACELL THERAPEUTICS CORP (BCTX)

Company Profile

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. The company is headquartered in West Vancouver, British Columbia. The company went IPO on 2006-10-12. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The firm is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The firm is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The firm is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

Company Info

BRIACELL THERAPEUTICS CORP

3rd Floor, Bellevue Centre,, 235-15th Str

West Vancouver BRITISH COLUMBIA V7T 2X1

P: 16049211810

CEO: William V. Williams

Employees: 0

Website: https://briacell.com/